Structure-based virtual screening of FGFR inhibitors: Cross-decoys and induced-fit effect

BioDrugs

Volumn 21, Issue 1, 2007, Pages 31-45

  Rabal, Obdulia ^a   Schneider, Gisbert ^b   Borrell, Jose I ^a   Teixidó, Jordi ^a  

^a INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE; FIBROBLAST GROWTH FACTOR RECEPTOR; NAPHTHYRIDINE DERIVATIVE; OXINDOLE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; UREA DERIVATIVE;

ARTICLE; BINDING SITE; COMPLEX FORMATION; DRUG SCREENING; DRUG STRUCTURE; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR BINDING; SCORING SYSTEM;

BINDING SITES; CRYSTALLIZATION; PROTEIN CONFORMATION; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 33846902392     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721010-00005     Document Type: Article

References (56)

1. Wang R, Lu Y, Wang S. Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 2003 Jun; 46 (12): 2287-303
2. Ferrara P, Gohlke H, Price DJ, et al. Assessing scoring functions for protein-ligand interactions. J Med Chem 2004 Jun; 47 (12): 3032-47
3. Kellenberger E, Rodrigo J, Muller P, et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins 2004 Nov; 57 (2): 225-42
4. Perez C, Ortiz AR. Evaluation of docking functions for protein-ligand docking. J Med Chem 2001; 44: 3768-85
5. Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: comparative data on docking algorithms. J Med Chem 2004 Jan; 47 (3): 558-65
6. Warren GL, Andrews CV, Capelli A, et al. A critical assessment of docking programs and scoring functions. J Med Chem 2006 Oct 5; 49 (20): 5912-31
7. Feher M. Consensus scoring for protein-ligand interactions. Drug Discov Today 2006 May; 11 (9-10): 421-8
8. Charifson PS, Corkery JJ, Murcko MA, et al. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999 Dec; 42 (25): 5100-9
9. Wang R, Wang S. How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci 2001 Sep-Oct; 41(5): 1422-6
10. Verdonk ML, Cole JC, Hartshorn MJ, et al. Virtual screening using protein-ligand docking: avoiding artificial enrichment. J Chem Inf Comput Sci 2004 May-Jun; 44(3): 793-806
11. Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997 Apr; 267 (3): 727-48
12. Ferrari AM, Wei BQ, Costantino L, et al. Soft docking and multiple receptor conformations in virtual screening. J Med Chem 2004 Oct; 47 (21): 5076-84
13. Claussen H, Bunning C, Rarey M, et al. FlexE: Efficient molecular docking considering protein structure variations. J Mol Biol 2001 Apr; 308 (2): 377-95
14. Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Design 2006; 67 (1): 83-4
15. Murray CW, Baxter CA, Frenkel AD. The sensitivity of the results of molecular docking to induced-fit effects: application to thrombin, thermolysin and neuraminidase. J Comp-Aided Mol Design 1999 Nov; 13 (6): 547-62
16. Birch L, Murray CW, Hartshorn MJ, et al. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. J Comp-Aided Mol Design 2002 Dec; 16 (12): 855-69
17. Erickson JA, Jalaie M, Robertson DH, et al. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem 2004 Jan; 47 (1): 45-55
18. Thomas MP, McInnes C, Fischerr P. Protein structures in virtual screening: a case study with CDK2. J Med Chem 2006 Jan; 49 (1): 92-104
19. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-98
20. McGovern SL, Shoichet BK. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem 2003 Jul; 46 (14): 2895-907
21. Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol 2004 Mar; 337 (1): 209-25
22. Wei BQ, Weaver LH, Ferrari AM, et al. Testing a flexible-receptor docking algorithm in a model binding site. J Mol Biol 2004 Apr; 337 (5): 1161-82
23. Cavasotto CN, Kovacs JA, Abagyan RA. Representing receptor flexibility in ligand docking through relevant normal modes. J Am Chem Soc 2005 Jul; 127 (6): 9632-40
24. Kovacs JA, Cavasotto CN, Abagyan RA. Conformational sampling of protein flexibility in generalized coordinates: application to ligand docking. J Comput Theor Nanosci 2005 Sep; 2 (3): 354-61
25. Cavasotto CN, Orry AJ, Abagyan RA. The challenge of considering receptor flexibility in ligand docking and virtual screening. Curr Comput Aided Drug Des 2005 Oct; 1 (4): 423-40
26. May A, Zacharias M. Accounting for global protein deformability during protein-protein and protein-ligand docking. Biochim Biophys Acta 2005 Dec; 1754 (1-2): 225-31
27. Teague SJ. Implications of protein flexibility for drug discovery. Nat Rev Drug Discov 2003 Jul; 2 (7): 527-41
28. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 159-78
29. Grose R, Dickson C. Fibroblast growth factor signalling in tumorigenesis. Cytokine Growth Factor Rev 2005 Apr; 16 (2): 179-86
30. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. Embo J 1998 Oct; 17 (20): 5896-904
31. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997 May; 276: 955-60
32. Alasdair TRL, Jackson RM. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005 May; 21 (9): 1908-16
33. Brady GP, Stouten PFW. Fast prediction and visualization of protein binding pockets with PASS. J Comp-Aided Mol Design 2000 May; 14 (4): 383-401
34. Hetényi C, Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 2002 Jul; 11 (7): 1729-37
35. Morris GM, Goodsell DS, Huey R, et al. Automated docking using a lamarckian genetic algorithm and a empirical binding free energy function. J Comput Chem 1998; 19: 1639-62
36. MOE, molecular operating environment [computer program]. Montreal (PQ): Chemical Computing Group, 2004
37. Hamby JM, Connolly CJC, Schroeder MC, et al. Structure-activity relationships for a novel series of Pyrido[2,3-d] pyrimidine tyrosine kinase inhibitors. J Med Chem 1997 Jul; 40 (15): 2296-303
38. Klutchko SR, Hamby JM, Boschelli DH, et al. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones: structure-activity relationships against selected tyrosine kinases and in vitro and in vitro anticancer activity. J Med Chem 1998 Aug; 41 (17): 3276-92
39. Boschelli DH, Wu Z, Klutchko SR, et al. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J Med Chem 1998 Oct; 41 (22): 4365-77
40. Connolly CJC, Hamby JM, Schroeder MC, et al. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]Pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Lett Letters 1997; 7 (18): 2415-20
41. Schroeder M, Hamby JM, Connolly CJC, et al. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas: structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vitro anticancer activity. J Med Chem 2001 Jun; 44 (12): 1915-26
42. Thompson AM, Rewcastle GW, Boushelle SL, et al. Synthesis and structure-activity relationships of 7-subsituted 3-(2,6-Dichlorophenyl)-1,- naphthyridin-2(1H)-ones as selective inhibitors of pp60c-src. J Med Chem 2000 Aug; 43 (16): 3134-47
43. Sun L, Tran N, Liang C, et al. Design, synthesis, and evaluations of substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J Med Chem 1999 Dec; 42 (25): 5120-30
44. Sun L, Tran N, Liang C, et al. Identification of substituted 3-[(4,5,6,7-Tetrahydro-1H, indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGFR-R1, and PDGFR-Rβ tyrosine kinases. J Med Chem 2000 Jul; 43 (14): 2655-63
45. Palmer BD, Kraker AJ, Hartl BG, et al. Structure-activity relationships for 5-substituted 1-Phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem 1999 Jul; 42 (13): 2373-82
46. Hennequin LF, Thomas AP, Johnstone C, et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999 Dec; 42 (26): 5369-89
47. Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002 Mar; 45 (6): 1300-12
48. Buzko OV, Bishop AC, Shokat KM. Modified AutoDock for accurate docking of protein kinase inhibitors. J Comp-Aided Mol Design 2002; 16: 113-27
49. Pierce AC, Sandretto KL, Bermis GW. Kinase inhibitors and the case for C-H...O hydrogen bonds in protein-ligand binding. Proteins 2002 Dec; 49 (4): 567-76
50. Morris GM. Autodock: parameters. The Scripps Research Institute (La Jolla) [online]. Available from URL: http://www.scripps.edu/mb/olson/doc/ autodock/parameters.html/ [Accessed 2006 Apr 19]
51. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980; 36: 3219-88
52. Stewart JJP. MOPAC 7/MOPAC 93 [computer program]. Tokyo: Fujitsu Limited, 1993
53. Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved protein-ligand docking using GOLD. Proteins Struct Funct Genet 2003; 52: 609-23
54. Schneider P, Schneider G. Collection of bioactive reference compounds for focused library design. QSAR Comb Sci 2003 Dec; 22 (7): 713-8
55. Diller DJ, Li RX. Kinases, homology models, and high throughput docking. J Med Chem 2003 Oct; 46 (22): 4638-47
56. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993 Dec; 234 (3): 779-815